[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Steris Corporation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":110},{"warningLetters":4,"total":109},[5,31,51,69,90],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},809,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-06-24T04:00:00Z\">06\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-06-05T04:00:00Z\">06\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsterling-distributors-706508-06052025\">Sterling Distributors\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Drug Supply Chain Security Act (DSCSA) Violations","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Dean Berry\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sterling Distributors\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4381 NW 124th Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Coral Springs\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33065-7634\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dberry@sterlingdistributors.net\"> dberry@sterlingdistributors.net  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 706508\u003C\u002Fp>\u003Cp>June 5, 2025\u003C\u002Fp>\u003Cp>FEI: 3007309337\u003C\u002Fp>\u003Cp>Dear Mr. Berry:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your wholesale distribution facility, Sterling Distributors (Sterling), FEI 3007309337, 4381 NW 124th Ave, Coral Springs, FL 33065-7634, from March 4, 2025, to March 6, 2025.\u003C\u002Fp>\u003Cp>The Drug Supply Chain Security Act (DSCSA) (Title II of Public Law 113-54), enacted by Congress on November 27, 2013, added section 582 to the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). Section 582 of the FD&amp;C Act (21 U.S.C. 360eee-1) specifies the requirements that certain entities in the pharmaceutical distribution supply chain (including wholesale drug distributors, as defined by the DSCSA) must follow related to product tracing, product identification, verification, and authorized trading partners. This warning letter summarizes significant violations by your firm of requirements in section 503(e) and 582(c) of the FD&amp;C Act. These requirements are intended to help preserve the security of the supply chain for certain prescription drug products, thereby protecting patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to Sterling at its Coral Springs, FL headquarters location on March 6, 2025. FDA reviewed Sterling’s response submitted on March 26, 2025.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>DSCSA Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During FDA’s inspection, our investigators observed that your firm failed to comply with various requirements of the DSCSA. Specific violations include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm engaged in wholesale distribution of prescription drug products without being appropriately licensed (FD&amp;C Act Section 503(e)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503(e)(1)(A) of the FD&amp;C Act, no person may engage in wholesale distribution of a prescription drug unless such person is (i) licensed by the State from which the drug is distributed, or if the State from which the drug is distributed has not established a licensure requirement, is licensed by the Secretary, and (ii) licensed by the State into which the drug is distributed if that State requires licensure of a person that distributes drugs into the State.\u003C\u002Fp>\u003Cp>Between August 29, 2024, and February 4, 2025, your firm received \u003Cstrong>(b)(4)\u003C\u002Fstrong> prescription drug products from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Between August 29, 2024, and February 5, 2025, your firm distributed these prescription drug units from its Florida facility to customers all over the U.S.\u003C\u002Fp>\u003Cp>For example, your firm conducted the following distributions of prescription drug products without the required licensure in Florida, Arkansas or Mississippi in violation of section 503(e) of the FD&amp;C Act:\u003C\u002Fp>\u003Cul>\u003Cli>On 11\u002F5\u002F2024, distribution of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #s \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> units were shipped under the same tracking number \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a pharmacy in Arkansas.\u003C\u002Fli>\u003Cli>On 12\u002F09\u002F2024, distribution of \u003Cstrong>(b)(4)\u003C\u002Fstrong> unit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, with lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> under shipment tracking number \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a pharmacy in Arkansas.\u003C\u002Fli>\u003Cli>On 12\u002F10\u002F2024, distribution of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot #s \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot #s \u003Cstrong>(b)(4)\u003C\u002Fstrong> under the shipment tracking number \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a pharmacy in Mississippi.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm was not able to demonstrate that Sterling held a prescription drug wholesale distribution license from Florida, where Sterling is located and from where Sterling distributes drugs. In addition, while both Arkansas and Mississippi require licensure of a person that distributes drugs into their states, Sterling was not licensed in either state at the time these prescription drugs were distributed to customers in these states.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm conducted transactions with trading partners that were not authorized (FD&amp;C Act Section 582(c)(3)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 582(c)(3) of the FD&amp;C Act, trading partners of wholesale drug distributors must be authorized trading partners. Under section 581(2)(B) of the FD&amp;C Act, to be authorized, a wholesale drug distributor must have a valid license under state law or section 583 of the FD&amp;C Act, in accordance with section 582(a)(6) of the FD&amp;C Act, and comply with the licensure reporting requirements of section 503(e) of the FD&amp;C Act. Under section 503(e)(2)(A) of the FD&amp;C Act, wholesale distributors must report to FDA, on an annual basis, “each State by which the person is licensed and the appropriate identification number of each such license; the name, address, and contact information of each facility at which, and all trade names under which, the person conducts business;” and “any significant disciplinary actions.”\u003C\u002Fp>\u003Cp>Sterling purchased product from a trading partner that was not authorized. Specifically, between August 29, 2024, and February 4, 2025, your firm purchased prescription \u003Cstrong>(b)(4)\u003C\u002Fstrong> products from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, another wholesale drug distributor. FDA has no record of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ever submitting the required annual reports to FDA regarding state licensure as required by section 503(e) of the FD&amp;C Act, and there is no evidence that \u003Cstrong>(b)(4)\u003C\u002Fstrong> held the appropriate state licensure. Further, Sterling could not demonstrate that it took any action to verify the licensure or reporting status of its direct trading partner, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to respond to requests for information from Federal and State Officials (FD&amp;C Act Section 582(c)(1)(C)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As required by section 582(c)(1)(C) of the FD&amp;C Act, upon a request from Federal or State officials investigating a suspect product or illegitimate product, wholesale drug distributors must respond, within one (1) business day to such a request with the applicable transaction statement and transaction information for the product.\u003C\u002Fp>\u003Cp>As part of its investigation into suspect or illegitimate product identified at a pharmacy in Arkansas, the Arkansas Board of Pharmacy (BoP) sent Sterling a subpoena for records, dated November 19, 2024, via certified mail commanding Sterling to produce records showing purchase information for all products Sterling sold and\u002For shipped into Arkansas since November 19, 2022. Sterling was not able to demonstrate that it responded to the inquiry, or that it responded to the Arkansas BoP’s follow-up subpoena dated January 14, 2025. After Sterling’s non-response, the Arkansas BoP suspended Sterling’s Arkansas medical gas license. Sterling was notified of this decision in a February 14, 2025, letter sent via certified mail. In addition, the Mississippi BoP first reached out to Sterling via phone call on or around January 8, 2025, seeking information as part of its investigation into suspect or illegitimate product identified at a pharmacy in Mississippi. On January 23, 2025, the Mississippi BoP followed up via email and certified mail requesting invoices for any medications Sterling shipped to Mississippi since January 1, 2022. During the inspection, Sterling acknowledged that it had been contacted by the Arkansas and Mississippi BoP. Sterling was unable to demonstrate that it responded to the Mississippi BoP.\u003C\u002Fp>\u003Cp>Additionally, when FDA presented Sterling with a 582(c)(1)(C) request for information letter on March 4, 2025, your firm did not provide FDA with the applicable transaction information and transaction statement for the products subject to the request. In fact, in response to this request by FDA, you stated, by letter dated March 5, 2025, that Sterling “does not maintain such records in the ordinary course.”\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to identify suspect product in its possession or control (FD&amp;C Act section 582(c)(4)(A)(i)), promptly conduct an investigation with trading partners to determine whether the suspect product was an illegitimate product (FD&amp;C Act Section 582(c)(4)(A)(i)(II)), determine, in coordination with the manufacturer, whether product in its possession or control is illegitimate (FD&amp;C Act Section 582(c)(4)(B)), respond to notifications of illegitimate product from trading partners (FD&amp;C Act Section 582(c)(4)(B)(iii)), and make notifications of illegitimate product to FDA and trading partners (FD&amp;C Act Section 582(c)(4)(B)(ii)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 582(c)(4)(A) of the FD&amp;C Act, wholesale drug distributors must determine whether product in its possession or control is suspect product. Under section 582(c)(4)(A)(i)(II), upon making a determination that a product in its possession or control is a suspect product, a wholesale drug distributor must promptly conduct an investigation in coordination with trading partners, where applicable, to determine whether the product is an illegitimate product. This determination must be made in coordination with the product’s manufacturer (see FD&amp;C Act section 582(c)(4)(B)(i)). In addition, under section 582(c)(4)(B)(iii) of the FD&amp;C Act, wholesale drug distributors must respond to a notification of illegitimate product from a trading partner by identifying all illegitimate product subject to the notification in the wholesale drug distributor’s possession or control, including any product that is subsequently received, and performing the activities specified in section 582(c)(4)(A) of the FD&amp;C Act, including, but not limited to, quarantining and dispositioning any product within the possession or control of the wholesale distributor. Further, under section 582(c)(4)(B)(ii) of the FD&amp;C Act, not later than 24 hours upon determining that a product in its possession or control is an illegitimate product, a wholesale drug distributor must notify FDA, and all immediate trading partners that the wholesale drug distributor has reason to believe may have received the illegitimate product, that the product is illegitimate.\u003C\u002Fp>\u003Cp>On December 4, 2024, Sterling was notified by one of its trading partners, a dispenser, that the dispenser was concerned it had received “mispackaged” \u003Cstrong>(b)(4)\u003C\u002Fstrong> from Sterling after product was returned to the dispenser by a patient. At that point, Sterling was obligated to promptly conduct the investigation specified in 582(c)(4)(A)(i)(II) of the FD&amp;C Act; yet Sterling failed to do so. Based on photos of the returned product, the product’s manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, later determined that the product was counterfeit and an illegitimate product. The product was not a genuine unit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> but rather a unit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with falsified \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeling. The dispenser returned the product to Sterling on December 5, 2024. This further obligated Sterling to promptly conduct the investigation specified in 582(c)(4)(A)(i)(II); yet Sterling again failed to do so. Instead, Sterling returned the product to its supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, without conducting its own investigation.\u003C\u002Fp>\u003Cp>On December 17, 2024, \u003Cstrong>(b)(4)\u003C\u002Fstrong> contacted Sterling about the unit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with falsified \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeling as a part of their investigation into the counterfeit and illegitimate product. This again obligated Sterling to promptly conduct the investigation specified in 582(c)(4)(A)(i)(II); yet Sterling again failed to do so. \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed-up with Sterling via voice message and email on December 19, 2024, and January 3, 2025. Sterling could not provide any evidence during the inspection that it cooperated with the manufacturer’s investigation into this product. Sterling also could not provide any evidence that it coordinated with the manufacturer to identify illegitimate product in Sterling’s possession or control, including product subsequently received. Evidence collected during the inspection indicates that Sterling continued to receive product with the same lot number as the product subject to the notification of illegitimate product, obtained through the same distributor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, until January 28, 2025. Your firm failed to quarantine such product and otherwise investigate. Your firm continued distributing product with the same lot number until February 3, 2025, nearly two months after you were first made aware of having distributed illegitimate product from this supplier labeled with this lot number.\u003C\u002Fp>\u003Cp>Sterling did not notify FDA of the illegitimate product and was not able to demonstrate that it notified immediate trading partners that Sterling had reason to believe may have also received the illegitimate product. Invoices collected during the inspection indicate that Sterling knew or should have known that it distributed illegitimate product obtained from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to other dispenser customers. Sterling nevertheless continued to receive product from \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing the same lot number that was the subject of the notification of illegitimate product until January 28, 2024, and Sterling continued distributing product containing that lot number until February 3, 2025.\u003C\u002Fp>\u003Cp>Sterling’s actions are especially concerning because certain \u003Cstrong>(b)(4)\u003C\u002Fstrong> products, like those Sterling purchased from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. In addition, counterfeit \u003Cstrong>(b)(4)\u003C\u002Fstrong> has been the subject of multiple FDA\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> consumer alerts\u003Cem>\u003Cstrong>\u003Csup>5, 6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> over the past several years.\u003C\u002Fp>\u003Cp>FDA has provided some specific transaction scenarios that could significantly increase the risk of suspect product entering the drug supply chain, and has recommended that trading partners be particularly diligent when engaging in such transactions.\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Such scenarios include:\u003C\u002Fp>\u003Cul>\u003Cli>Purchasing product that is generally in high demand in the U.S. market;\u003C\u002Fli>\u003Cli>Purchasing product that has been or is the subject of a public alert or announcement related to drug quality issued by a trading partner or FDA;\u003C\u002Fli>\u003Cli>Purchasing product that has been or is the subject of an FDA counterfeit alert;\u003C\u002Fli>\u003Cli>Purchasing product from a trading partner that has been involved in business transactions where they sold or delivered illegitimate product; and\u003C\u002Fli>\u003Cli>Purchasing product where the finished dosage form seems questionable (e.g., it has a different shape or color from the FDA-approved product, a different or unusual imprint, an unusual odor, or there are signs of poor quality like chips or cracks in tablet coatings or smeared or unclear ink imprints).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Nevertheless, Sterling failed to comply with its verification obligations to ensure that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> products purchased from \u003Cstrong>(b)(4)\u003C\u002Fstrong> were legitimate product. In addition, Sterling continued to distribute product it purchased from \u003Cstrong>(b)(4)\u003C\u002Fstrong> through February 5, 2025, well after your firm first became aware that \u003Cstrong>(b)(4)\u003C\u002Fstrong> may have distributed illegitimate product. And, as discussed above, in addition to failing to identify such product as suspect product, your firm was not able to demonstrate that Sterling conducted an investigation in coordination with trading partners after receiving a returned unit of counterfeit \u003Cstrong>(b)(4)\u003C\u002Fstrong> from a pharmacy to whom your firm distributed product, responded to notifications of illegitimate product from trading partners, or made notifications of illegitimate product to trading partners.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Your firm failed to collect and maintain transaction information and transaction statements (FD&amp;C Act Section 582(c)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 582(c)(1) of the FD&amp;C Act, wholesale drug distributors must not accept ownership of a product unless the previous owner provides the transaction information and transaction statement for the product, and must provide subsequent purchasers the transaction information and a transaction statement for the product. Under section 582(c)(1)(A)(v), a wholesale distributor must capture the transaction information and transaction statement for each transaction and maintain such information for not less than 6 years.\u003C\u002Fp>\u003Cp>Sterling could not demonstrate that your firm collected and maintained transaction information and transaction statements that should have been received from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Sterling could not demonstrate that your firm shared transaction information and transaction statements with Sterling’s downstream trading partners.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Your firm failed to have systems in place to enable compliance with the verification requirements of the DSCSA. (FD&amp;C Act Sections 582(c)(4)(A) and (B)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under sections 582(c)(4)(A) and (B) of the FD&amp;C Act, wholesale drug distributors must have systems in place to enable the wholesale distributor to comply with the verification requirements of the DSCSA, including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Identifying and determining whether a product in its possession or control is a suspect product;\u003C\u002Fli>\u003Cli>Promptly conducting an investigation in coordination with trading partners, as applicable, to determine whether the product is an illegitimate product, which must include, among other things, investigating to determine whether the product is an illegitimate product and verifying the product at the package level;\u003C\u002Fli>\u003Cli>Quarantining and disposing of any illegitimate product in the wholesale distributor’s possession or control;\u003C\u002Fli>\u003Cli>Taking reasonable and appropriate steps to assist a trading partner with disposition of an illegitimate product not in the possession or control of the wholesale distributor; and\u003C\u002Fli>\u003Cli>Maintaining records of the investigation of a suspect product and disposition of illegitimate product for not less than 6 years.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm was not able to produce complete and accurate standard operating procedures (SOPs), or other systems related to compliance with the verification requirements of the DSCSA, that would enable Sterling to comply with the verification requirements under sections 582(c)(4)(A) and (B) of the FD&amp;C Act. Sterling provided the FDA investigators with \u003Cstrong>(b)(4)\u003C\u002Fstrong> policy documents and standard operating procedures; none address the verification requirements of the DSCSA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Your Response to the FDA Form 483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed your March 26, 2025, response to our Form FDA 483 in detail. FDA acknowledges the corrective actions Sterling has taken and committed to, but FDA finds Sterling’s response to be inadequate. Sterling’s response does not provide adequate information about how Sterling will ensure compliance with the FD&amp;C Act moving forward. In addition, Sterling’s response does not acknowledge that, as early as November 2024, your firm knew or should have known that it was distributing prescription drugs without a wholesale distributor of prescription drugs license, and that by December 2024, your firm was distributing suspect and illegitimate product. Nevertheless, Sterling chose not to follow-up on those notifications.\u003C\u002Fp>\u003Cp>In your firm’s response, you state that you were not alerted to the fact the products at issue were potentially counterfeit, and therefore suspect and illegitimate.\u003C\u002Fp>\u003Cp>During the course of their investigations, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the Arkansas and Mississippi BoP made multiple attempts to contact Sterling. \u003Cstrong>(b)(4)\u003C\u002Fstrong> tried to contact your firm on at least three (3) occasions regarding product it was investigating that had been distributed by your firm. You did not respond to assist in \u003Cstrong>(b)(4)\u003C\u002Fstrong> investigation. As a result of your lack of cooperation with \u003Cstrong>(b)(4)\u003C\u002Fstrong> investigation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> was unable to provide you with additional information. Similarly, if Sterling had responded to the requests for information from the Mississippi and Arkansas State BoP, including the subpoena your firm received from Arkansas BoP, even to seek clarity about the requests, Sterling would have better understood the scope of the respective investigations. Instead, Sterling did not respond to the requests or the subpoena and did not participate in these investigations, in violation of the DSCSA requirements as outlined extensively above. The lack of specific language in these notifications and requests for information does not absolve Sterling of its obligations under the DSCSA. Sterling had significant notice and reason to know that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the manufacturer of the products distributed by Sterling, and multiple state BoP were investigating Sterling’s distribution of prescription drug products, and your firm did not act.\u003C\u002Fp>\u003Cp>Sterling’s response does not explain how your firm will process notifications of illegitimate product and requests for information moving forward. It does not address how Sterling will ensure it is responsive and cooperative, as required by DSCSA, when contacted about suspect and illegitimate product investigations in the future.\u003C\u002Fp>\u003Cp>Other reasons Sterling’s response is insufficient include, but are not limited to, the following:\u003C\u002Fp>\u003Cul>\u003Cli>Sterling’s response explains that your firm is updating its policies and procedures for reviewing the credentials of vendors. Sterling has not yet explained what these policies and procedures will entail, nor provided a timeline for submitting these revised policies to FDA.\u003C\u002Fli>\u003Cli>In its response, Sterling explains that its vendor purchase order requires vendors to verify that all products sold to Sterling Distributors “have been stored following manufacturer recommendations and have never been previously distributed to any entity,” and that products “are legitimate products purchased from FDA approved manufacturers.” The response does not otherwise explain how Sterling plans to audit its vendors and ensure that product it receives is legitimate product from authorized sources.\u003C\u002Fli>\u003Cli>Given your firm’s confusion over the prescription status of drugs you have previously distributed, Sterling’s response does not explain how your firm will identify drugs as either an over-the-counter drug or a prescription drug.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>DSCSA Resources\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As explained above, your firm has failed to comply with a number of DSCSA provisions. Please see FDA’s guidance documents,\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> including those listed below, for additional information about the DSCSA requirements noted above:\u003C\u002Fp>\u003Cul>\u003Cli>Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs, Final Guidance for Industry, December 2023, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F117950\u002Fdownload.\u003C\u002Fli>\u003Cli>Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act, Final Guidance for Industry, March 2023, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F111468\u002Fdownload.\u003C\u002Fli>\u003Cli>Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, Final Guidance, June 2021, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F88790\u002Fdownload.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sterling’s response to FDA Form 483 does not indicate that sufficient remediation efforts have been taken. FDA is sending this compliance letter to Sterling because of the inherent risk to the supply chain when firms do not comply with the provisions of the DSCSA.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address the violations described herein may result in regulatory or legal action without further notice, including seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of your receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct the violations identified in this warning letter. Please include an explanation of each step being taken to prevent the recurrence of violations and include copies of related documentation. If you disagree with the characterization of the violations of the FD&amp;C Act in this warning letter, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the corrections.\u003C\u002Fp>\u003Cp>Please send your electronic reply, or any questions regarding the contents of this letter, to: DSCSAInspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Please identify your responses with the unique identifier: CMS 706508.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Sangeeta Vaswani Chatterjee, Pharm.D.\u003Cbr>Acting Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA maintains a reporting database that contains information submitted by wholesale drug distributors. Please note that reporting by a wholesale drug distributor provider does not mean the facility is licensed or approved by FDA or the facility is in compliance with applicable state and federal regulations. Check licensure of wholesale drug distributors and third-party logistics providers for more information.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> See FDA’s \u003Cem>Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification\u003C\u002Fem>, Final Guidance, June 2021, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F88790\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> FDA guidance documents can be found on our website: Drug Supply Chain Security Act Law and Policies | FDA\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Dean Berry\n\nRecipient Title\n\nPresident\n\nSterling Distributors\n\n4381 NW 124th Ave\n\nCoral Springs, FL 33065-7634\n\nUnited States\n\ndberry@sterlingdistributors.net\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 706508\nJune 5, 2025\nFEI: 3007309337\nDear Mr. Berry:\nThe U.S. Food and Drug Administration (FDA) inspected your wholesale distribution facility, Sterling Distributors (Sterling), FEI 3007309337, 4381 NW 124th Ave, Coral Springs, FL 33065-7634, from March 4, 2025, to March 6, 2025.\nThe Drug Supply Chain Security Act (DSCSA) (Title II of Public Law 113-54), enacted by Congress on November 27, 2013, added section 582 to the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 582 of the FD&C Act (21 U.S.C. 360eee-1) specifies the requirements that certain entities in the pharmaceutical distribution supply chain (including wholesale drug distributors, as defined by the DSCSA) must follow related to product tracing, product identification, verification, and authorized trading partners. This warning letter summarizes significant violations by your firm of requirements in section 503(e) and 582(c) of the FD&C Act. These requirements are intended to help preserve the security of the supply chain for certain prescription drug products, thereby protecting patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.\nFDA issued a Form FDA 483 to Sterling at its Coral Springs, FL headquarters location on March 6, 2025. FDA reviewed Sterling’s response submitted on March 26, 2025.\nDSCSA Violations\nDuring FDA’s inspection, our investigators observed that your firm failed to comply with various requirements of the DSCSA. Specific violations include, but may not be limited to, the following:\n1. Your firm engaged in wholesale distribution of prescription drug products without being appropriately licensed (FD&C Act Section 503(e)).\nUnder section 503(e)(1)(A) of the FD&C Act, no person may engage in wholesale distribution of a prescription drug unless such person is (i) licensed by the State from which the drug is distributed, or if the State from which the drug is distributed has not established a licensure requirement, is licensed by the Secretary, and (ii) licensed by the State into which the drug is distributed if that State requires licensure of a person that distributes drugs into the State.\nBetween August 29, 2024, and February 4, 2025, your firm received (b)(4) prescription drug products from (b)(4). Between August 29, 2024, and February 5, 2025, your firm distributed these prescription drug units from its Florida facility to customers all over the U.S.\nFor example, your firm conducted the following distributions of prescription drug products without the required licensure in Florida, Arkansas or Mississippi in violation of section 503(e) of the FD&C Act:\nOn 11\u002F5\u002F2024, distribution of (b)(4) units of (b)(4) with lot #s (b)(4). (b)(4) units were shipped under the same tracking number (b)(4) to a pharmacy in Arkansas.\nOn 12\u002F09\u002F2024, distribution of (b)(4) unit of (b)(4), with lot # (b)(4) under shipment tracking number (b)(4) to a pharmacy in Arkansas.\nOn 12\u002F10\u002F2024, distribution of (b)(4) units of (b)(4), lot #s (b)(4), and (b)(4) units of (b)(4), lot #s (b)(4) under the shipment tracking number (b)(4) to a pharmacy in Mississippi.\nYour firm was not able to demonstrate that Sterling held a prescription drug wholesale distribution license from Florida, where Sterling is located and from where Sterling distributes drugs. In addition, while both Arkansas and Mississippi require licensure of a person that distributes drugs into their states, Sterling was not licensed in either state at the time these prescription drugs were distributed to customers in these states.\n2. Your firm conducted transactions with trading partners that were not authorized (FD&C Act Section 582(c)(3)).\nUnder section 582(c)(3) of the FD&C Act, trading partners of wholesale drug distributors must be authorized trading partners. Under section 581(2)(B) of the FD&C Act, to be authorized, a wholesale drug distributor must have a valid license under state law or section 583 of the FD&C Act, in accordance with section 582(a)(6) of the FD&C Act, and comply with the licensure reporting requirements of section 503(e) of the FD&C Act. Under section 503(e)(2)(A) of the FD&C Act, wholesale distributors must report to FDA, on an annual basis, “each State by which the person is licensed and the appropriate identification number of each such license; the name, address, and contact information of each facility at which, and all trade names under which, the person conducts business;” and “any significant disciplinary actions.”\nSterling purchased product from a trading partner that was not authorized. Specifically, between August 29, 2024, and February 4, 2025, your firm purchased prescription (b)(4) products from (b)(4), another wholesale drug distributor. FDA has no record of (b)(4) ever submitting the required annual reports to FDA regarding state licensure as required by section 503(e) of the FD&C Act, and there is no evidence that (b)(4) held the appropriate state licensure. Further, Sterling could not demonstrate that it took any action to verify the licensure or reporting status of its direct trading partner, (b)(4).1\n3. Your firm failed to respond to requests for information from Federal and State Officials (FD&C Act Section 582(c)(1)(C)).\nAs required by section 582(c)(1)(C) of the FD&C Act, upon a request from Federal or State officials investigating a suspect product or illegitimate product, wholesale drug distributors must respond, within one (1) business day to such a request with the applicable transaction statement and transaction information for the product.\nAs part of its investigation into suspect or illegitimate product identified at a pharmacy in Arkansas, the Arkansas Board of Pharmacy (BoP) sent Sterling a subpoena for records, dated November 19, 2024, via certified mail commanding Sterling to produce records showing purchase information for all products Sterling sold and\u002For shipped into Arkansas since November 19, 2022. Sterling was not able to demonstrate that it responded to the inquiry, or that it responded to the Arkansas BoP’s follow-up subpoena dated January 14, 2025. After Sterling’s non-response, the Arkansas BoP suspended Sterling’s Arkansas medical gas license. Sterling was notified of this decision in a February 14, 2025, letter sent via certified mail. In addition, the Mississippi BoP first reached out to Sterling via phone call on or around January 8, 2025, seeking information as part of its investigation into suspect or illegitimate product identified at a pharmacy in Mississippi. On January 23, 2025, the Mississippi BoP followed up via email and certified mail requesting invoices for any medications Sterling shipped to Mississippi since January 1, 2022. During the inspection, Sterling acknowledged that it had been contacted by the Arkansas and Mississippi BoP. Sterling was unable to demonstrate that it responded to the Mississippi BoP.\nAdditionally, when FDA presented Sterling with a 582(c)(1)(C) request for information letter on March 4, 2025, your firm did not provide FDA with the applicable transaction information and transaction statement for the products subject to the request. In fact, in response to this request by FDA, you stated, by letter dated March 5, 2025, that Sterling “does not maintain such records in the ordinary course.”\n4. Your firm failed to identify suspect product in its possession or control (FD&C Act section 582(c)(4)(A)(i)), promptly conduct an investigation with trading partners to determine whether the suspect product was an illegitimate product (FD&C Act Section 582(c)(4)(A)(i)(II)), determine, in coordination with the manufacturer, whether product in its possession or control is illegitimate (FD&C Act Section 582(c)(4)(B)), respond to notifications of illegitimate product from trading partners (FD&C Act Section 582(c)(4)(B)(iii)), and make notifications of illegitimate product to FDA and trading partners (FD&C Act Section 582(c)(4)(B)(ii)).\nUnder section 582(c)(4)(A) of the FD&C Act, wholesale drug distributors must determine whether product in its possession or control is suspect product. Under section 582(c)(4)(A)(i)(II), upon making a determination that a product in its possession or control is a suspect product, a wholesale drug distributor must promptly conduct an investigation in coordination with trading partners, where applicable, to determine whether the product is an illegitimate product. This determination must be made in coordination with the product’s manufacturer (see FD&C Act section 582(c)(4)(B)(i)). In addition, under section 582(c)(4)(B)(iii) of the FD&C Act, wholesale drug distributors must respond to a notification of illegitimate product from a trading partner by identifying all illegitimate product subject to the notification in the wholesale drug distributor’s possession or control, including any product that is subsequently received, and performing the activities specified in section 582(c)(4)(A) of the FD&C Act, including, but not limited to, quarantining and dispositioning any product within the possession or control of the wholesale distributor. Further, under section 582(c)(4)(B)(ii) of the FD&C Act, not later than 24 hours upon determining that a product in its possession or control is an illegitimate product, a wholesale drug distributor must notify FDA, and all immediate trading partners that the wholesale drug distributor has reason to believe may have received the illegitimate product, that the product is illegitimate.\nOn December 4, 2024, Sterling was notified by one of its trading partners, a dispenser, that the dispenser was concerned it had received “mispackaged” (b)(4) from Sterling after product was returned to the dispenser by a patient. At that point, Sterling was obligated to promptly conduct the investigation specified in 582(c)(4)(A)(i)(II) of the FD&C Act; yet Sterling failed to do so. Based on photos of the returned product, the product’s manufacturer, (b)(4), later determined that the product was counterfeit and an illegitimate product. The product was not a genuine unit of (b)(4) but rather a unit of (b)(4) with falsified (b)(4) labeling. The dispenser returned the product to Sterling on December 5, 2024. This further obligated Sterling to promptly conduct the investigation specified in 582(c)(4)(A)(i)(II); yet Sterling again failed to do so. Instead, Sterling returned the product to its supplier, (b)(4), without conducting its own investigation.\nOn December 17, 2024, (b)(4) contacted Sterling about the unit of (b)(4) with falsified (b)(4) labeling as a part of their investigation into the counterfeit and illegitimate product. This again obligated Sterling to promptly conduct the investigation specified in 582(c)(4)(A)(i)(II); yet Sterling again failed to do so. (b)(4) followed-up with Sterling via voice message and email on December 19, 2024, and January 3, 2025. Sterling could not provide any evidence during the inspection that it cooperated with the manufacturer’s investigation into this product. Sterling also could not provide any evidence that it coordinated with the manufacturer to identify illegitimate product in Sterling’s possession or control, including product subsequently received. Evidence collected during the inspection indicates that Sterling continued to receive product with the same lot number as the product subject to the notification of illegitimate product, obtained through the same distributor, (b)(4), until January 28, 2025. Your firm failed to quarantine such product and otherwise investigate. Your firm continued distributing product with the same lot number until February 3, 2025, nearly two months after you were first made aware of having distributed illegitimate product from this supplier labeled with this lot number.\nSterling did not notify FDA of the illegitimate product and was not able to demonstrate that it notified immediate trading partners that Sterling had reason to believe may have also received the illegitimate product. Invoices collected during the inspection indicate that Sterling knew or should have known that it distributed illegitimate product obtained from (b)(4) to other dispenser customers. Sterling nevertheless continued to receive product from (b)(4) containing the same lot number that was the subject of the notification of illegitimate product until January 28, 2024, and Sterling continued distributing product containing that lot number until February 3, 2025.\nSterling’s actions are especially concerning because certain (b)(4) products, like those Sterling purchased from (b)(4), (b)(4)2 (b)(4)3. In addition, counterfeit (b)(4) has been the subject of multiple FDA4 and (b)(4) consumer alerts5, 6 over the past several years.\nFDA has provided some specific transaction scenarios that could significantly increase the risk of suspect product entering the drug supply chain, and has recommended that trading partners be particularly diligent when engaging in such transactions.7 Such scenarios include:\nPurchasing product that is generally in high demand in the U.S. market;\nPurchasing product that has been or is the subject of a public alert or announcement related to drug quality issued by a trading partner or FDA;\nPurchasing product that has been or is the subject of an FDA counterfeit alert;\nPurchasing product from a trading partner that has been involved in business transactions where they sold or delivered illegitimate product; and\nPurchasing product where the finished dosage form seems questionable (e.g., it has a different shape or color from the FDA-approved product, a different or unusual imprint, an unusual odor, or there are signs of poor quality like chips or cracks in tablet coatings or smeared or unclear ink imprints).\nNevertheless, Sterling failed to comply with its verification obligations to ensure that the (b)(4) products purchased from (b)(4) were legitimate product. In addition, Sterling continued to distribute product it purchased from (b)(4) through February 5, 2025, well after your firm first became aware that (b)(4) may have distributed illegitimate product. And, as discussed above, in addition to failing to identify such product as suspect product, your firm was not able to demonstrate that Sterling conducted an investigation in coordination with trading partners after receiving a returned unit of counterfeit (b)(4) from a pharmacy to whom your firm distributed product, responded to notifications of illegitimate product from trading partners, or made notifications of illegitimate product to trading partners.\n5. Your firm failed to collect and maintain transaction information and transaction statements (FD&C Act Section 582(c)(1)).\nUnder section 582(c)(1) of the FD&C Act, wholesale drug distributors must not accept ownership of a product unless the previous owner provides the transaction information and transaction statement for the product, and must provide subsequent purchasers the transaction information and a transaction statement for the product. Under section 582(c)(1)(A)(v), a wholesale distributor must capture the transaction information and transaction statement for each transaction and maintain such information for not less than 6 years.\nSterling could not demonstrate that your firm collected and maintained transaction information and transaction statements that should have been received from (b)(4). Sterling could not demonstrate that your firm shared transaction information and transaction statements with Sterling’s downstream trading partners.\n6. Your firm failed to have systems in place to enable compliance with the verification requirements of the DSCSA. (FD&C Act Sections 582(c)(4)(A) and (B)).\nUnder sections 582(c)(4)(A) and (B) of the FD&C Act, wholesale drug distributors must have systems in place to enable the wholesale distributor to comply with the verification requirements of the DSCSA, including but not limited to:\nIdentifying and determining whether a product in its possession or control is a suspect product;\nPromptly conducting an investigation in coordination with trading partners, as applicable, to determine whether the product is an illegitimate product, which must include, among other things, investigating to determine whether the product is an illegitimate product and verifying the product at the package level;\nQuarantining and disposing of any illegitimate product in the wholesale distributor’s possession or control;\nTaking reasonable and appropriate steps to assist a trading partner with disposition of an illegitimate product not in the possession or control of the wholesale distributor; and\nMaintaining records of the investigation of a suspect product and disposition of illegitimate product for not less than 6 years.\nYour firm was not able to produce complete and accurate standard operating procedures (SOPs), or other systems related to compliance with the verification requirements of the DSCSA, that would enable Sterling to comply with the verification requirements under sections 582(c)(4)(A) and (B) of the FD&C Act. Sterling provided the FDA investigators with (b)(4) policy documents and standard operating procedures; none address the verification requirements of the DSCSA.\nYour Response to the FDA Form 483\nFDA has reviewed your March 26, 2025, response to our Form FDA 483 in detail. FDA acknowledges the corrective actions Sterling has taken and committed to, but FDA finds Sterling’s response to be inadequate. Sterling’s response does not provide adequate information about how Sterling will ensure compliance with the FD&C Act moving forward. In addition, Sterling’s response does not acknowledge that, as early as November 2024, your firm knew or should have known that it was distributing prescription drugs without a wholesale distributor of prescription drugs license, and that by December 2024, your firm was distributing suspect and illegitimate product. Nevertheless, Sterling chose not to follow-up on those notifications.\nIn your firm’s response, you state that you were not alerted to the fact the products at issue were potentially counterfeit, and therefore suspect and illegitimate.\nDuring the course of their investigations, (b)(4) and the Arkansas and Mississippi BoP made multiple attempts to contact Sterling. (b)(4) tried to contact your firm on at least three (3) occasions regarding product it was investigating that had been distributed by your firm. You did not respond to assist in (b)(4) investigation. As a result of your lack of cooperation with (b)(4) investigation, (b)(4) was unable to provide you with additional information. Similarly, if Sterling had responded to the requests for information from the Mississippi and Arkansas State BoP, including the subpoena your firm received from Arkansas BoP, even to seek clarity about the requests, Sterling would have better understood the scope of the respective investigations. Instead, Sterling did not respond to the requests or the subpoena and did not participate in these investigations, in violation of the DSCSA requirements as outlined extensively above. The lack of specific language in these notifications and requests for information does not absolve Sterling of its obligations under the DSCSA. Sterling had significant notice and reason to know that (b)(4), the manufacturer of the products distributed by Sterling, and multiple state BoP were investigating Sterling’s distribution of prescription drug products, and your firm did not act.\nSterling’s response does not explain how your firm will process notifications of illegitimate product and requests for information moving forward. It does not address how Sterling will ensure it is responsive and cooperative, as required by DSCSA, when contacted about suspect and illegitimate product investigations in the future.\nOther reasons Sterling’s response is insufficient include, but are not limited to, the following:\nSterling’s response explains that your firm is updating its policies and procedures for reviewing the credentials of vendors. Sterling has not yet explained what these policies and procedures will entail, nor provided a timeline for submitting these revised policies to FDA.\nIn its response, Sterling explains that its vendor purchase order requires vendors to verify that all products sold to Sterling Distributors “have been stored following manufacturer recommendations and have never been previously distributed to any entity,” and that products “are legitimate products purchased from FDA approved manufacturers.” The response does not otherwise explain how Sterling plans to audit its vendors and ensure that product it receives is legitimate product from authorized sources.\nGiven your firm’s confusion over the prescription status of drugs you have previously distributed, Sterling’s response does not explain how your firm will identify drugs as either an over-the-counter drug or a prescription drug.\nDSCSA Resources\nAs explained above, your firm has failed to comply with a number of DSCSA provisions. Please see FDA’s guidance documents,8 including those listed below, for additional information about the DSCSA requirements noted above:\nVerification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs, Final Guidance for Industry, December 2023, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F117950\u002Fdownload.\nDefinitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act, Final Guidance for Industry, March 2023, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F111468\u002Fdownload.\nDrug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, Final Guidance, June 2021, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F88790\u002Fdownload.\nConclusion\nSterling’s response to FDA Form 483 does not indicate that sufficient remediation efforts have been taken. FDA is sending this compliance letter to Sterling because of the inherent risk to the supply chain when firms do not comply with the provisions of the DSCSA.\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address the violations described herein may result in regulatory or legal action without further notice, including seizure and injunction.\nWithin fifteen (15) working days of your receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct the violations identified in this warning letter. Please include an explanation of each step being taken to prevent the recurrence of violations and include copies of related documentation. If you disagree with the characterization of the violations of the FD&C Act in this warning letter, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the corrections.\nPlease send your electronic reply, or any questions regarding the contents of this letter, to: DSCSAInspections@fda.hhs.gov.\nPlease identify your responses with the unique identifier: CMS 706508.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, Pharm.D.\nActing Director\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________________\n1 FDA maintains a reporting database that contains information submitted by wholesale drug distributors. Please note that reporting by a wholesale drug distributor provider does not mean the facility is licensed or approved by FDA or the facility is in compliance with applicable state and federal regulations. Check licensure of wholesale drug distributors and third-party logistics providers for more information.\n2 (b)(4)\n3 (b)(4)\n4 (b)(4)\n5 (b)(4)\n6 (b)(4)\n7 See FDA’s Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, Final Guidance, June 2021, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F88790\u002Fdownload.\n8 FDA guidance documents can be found on our website: Drug Supply Chain Security Act Law and Policies | FDA","Sterling Distributors","sterling-distributors-706508-06052025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsterling-distributors-706508-06052025","2026-10-26T08:10:05.921041+00:00","Warning Letter","Issued","2025-06-24","706508","Drugs","Mr. Dean Berry","2026-08-19T16:39:16.264+00:00","VIA UPS","2025-06-05",{"id":32,"raw":33,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1074,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2025-02-04T05:00:00Z\">02\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-19T05:00:00Z\">12\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffagron-compounding-services-llc-dba-fagron-sterile-service-698861-12192024\">Fagron Compounding Services, LLC dba Fagron Sterile Service\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason McGuire\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Vice President, Operations \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fagron Compounding Services, LLC dba Fagron Sterile Service\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8710 East 34th Street North\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wichita\u003C\u002Fspan>, \u003Cspan>KS\u003C\u002Fspan> \u003Cspan>67226-2636\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>WL # 698861\u003C\u002Fp>\u003Cp>12\u002F19\u002F2024\u003C\u002Fp>\u003Cp>Dear Mr. McGuire:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on October 2, 2015, and most recently on October 18, 2024. From June 18 to June 28, 2024, an FDA investigator inspected your facility, Fagron Compounding Services, LLC dba Fagron Sterile Services, located at 8710 East 34th Street North, Wichita, KS 67226. During the inspection, the investigator collected evidence that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your facility on June 28, 2024. FDA acknowledges receipt of your facility’s responses, dated July 19, 2024, August 30, 2024, September 27, 2024, and October 25, 2024. FDA further acknowledges that on August 15, 2024, your firm initiated a voluntary recall of four lots of Lidocaine HCl Injection, 2% due to lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator collected evidence of the following deficiencies with your facility’s drug product labels:\u003C\u002Fp>\u003Cp>1. The drug product label did not include the dosage form. Examples include: Tropicamide 1%\u002FCyclopentolate 1%\u002FPhenylephrine 2.5%\u002FKetorolac 0.5%, 5mL and Fentanyl Citrate 2mcg\u002FmL (100mcg\u002F50mL)\u002FRopivacaine HCl 0.15% (1.5mg\u002FmL) (75mg\u002F50mL).\u003C\u002Fp>\u003Cp>2. The drug product label did not include the established name of the drug. Examples include: Tropicamide 1%\u002FCyclopentolate 1%\u002FPhenylephrine 2.5%\u002FKetorolac 0.5%, 5mL; Sodium Citrate 4% (40mg\u002FmL) containing Gentamicin 320mcg\u002FmL Injection, 3mL, 5 mL, and 30 mL; and Epinephrine (1mg\u002FmL), Sterile Solution for Injection.\u003C\u002Fp>\u003Cp>3. The drug product label did not include a list of active ingredients identified by established name. Examples include: Tropicamide 1%\u002FCyclopentolate 1%\u002FPhenylephrine 2.5%\u002FKetorolac 0.5%, 5mL; Sodium Citrate 4% (40mg\u002FmL) containing Gentamicin 320mcg\u002FmL Injection, 3mL, 5 mL, and 30 mL; and Epinephrine (1mg\u002FmL), Sterile Solution for Injection.\u003C\u002Fp>\u003Cp>Further, the investigator collected evidence of the following deficiencies with your facility’s container labels:\u003C\u002Fp>\u003Cp>1. The container from which the individual units of the drug are removed for dispensing or for administration did not include directions for use, including, as appropriate, dosage and administration. Examples include: Epinephrine (1mg\u002FmL), Sterile Solution for Injection; Phenol Injection 6% (60 mg\u002FmL), in Sterile Water for Injection, 10 mL in Multi-Dose Vial; Sodium Citrate 4% (40mg\u002FmL) containing Gentamicin 320mcg\u002FmL Injection, 3mL, 5 mL, and 30 mL; and Dexamethasone Sodium Phosphate 10 mg\u002FmL Solution for Injection, 2 mL in Multi-Dose Vial.\u003C\u002Fp>\u003Cp>2. The container from which the individual units of the drug are removed for dispensing or for administration did not include a list of active ingredients identified by established name. Examples include: Tropicamide 1%\u002FCyclopentolate 1%\u002FPhenylephrine 2.5%\u002FKetorolac 0.5%, 5mL; Sodium Citrate 4% (40mg\u002FmL) containing Gentamicin 320mcg\u002FmL Injection, 3mL, 5 mL, and 30 mL; and Epinephrine (1mg\u002FmL), Sterile Solution for Injection.\u003C\u002Fp>\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\u003Cp>Specific violations are described below.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that.\u003C\u002Fp>\u003Cp>1. You did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\u003C\u002Fp>\u003Cp>2. Your firm produced drug products while construction was underway without adequate controls to prevent contamination of the product environment and products.\u003C\u002Fp>\u003Cp>The FDA investigator also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\u003Cp>2. Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition (21 CFR 211.56(a)).\u003C\u002Fp>\u003Cp>3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. We acknowledge your firm’s recall of four lots of Lidocaine HCl Injection, 2% due to lack of sterility assurance.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions due to lack of adequate supporting documentation. Pertaining to the \u003Cem>Chaetomium globosum\u003C\u002Fem> recovery referenced, you stated the operator “was in training at the time of the recovery.” The investigation into the recovery, DEV-2024-0174, states the operator, “was not fully trained” and “left unsupervised by a qualified trainer, which is a deviation” from procedure. Your firm identified this deviation after reviewing footage of batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, upon discovering this deviation, your investigation did not expand to other lots produced or operations conducted by the “not fully trained” operator.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient. You stated in your response, “For the personnel samples, the samples were taken after the completion of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process, prior to removal of waste and disinfection\u002Fsanitization of the ISO 5 hood and equipment. In review of the batch record, the operators for Succinylcholine lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Rocuronium lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lidocaine lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> had performed staging, support and \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities prior to taking the glove samples. This included sanitizing materials into the hood, removing filled bags, insertion of sterile needle into the bag ports and batch record documentation. None of these activities impacted the filling of the child batches as each child batch did not have a recovery and sterility testing for each passed.” We disagree with your assessment. The operator was involved in critical process parameters, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the parent batch. This parent batch was used to fill four child batches. The child batches were not \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We acknowledge your recall of child batches of the parent lot: Lidocaine HCl 2%, Lot# \u003Cstrong>(b)(4)\u003C\u002Fstrong>, within expiry on August 9, 2024.\u003C\u002Fp>\u003Cp>Please note, microbial contamination, when present, is not uniformly distributed within a batch; therefore, it may not be identified in a sterility test. Compounding facilities producing drug products intended to be sterile under insanitary conditions should not rely upon or cite a passing sterility test result as an indication of product sterility.\u003C\u002Fp>\u003Cp>We acknowledge your commitments in response to our concerns noted with your upcoming facility expansion. During the next FDA inspection, we will assess the potential impact of the upcoming planned construction activities on the quality of sterile drug products that were produced and distributed to patients.\u003C\u002Fp>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [\u003Cem>See\u003C\u002Fem> 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>In addition, regarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You have initiated CAPA-2024-0105 and CAPA-2024-0106 to address label issues concerning dosage form, established name of the drug and directions for use. However, no corrective actions have been provided to the agency to address label issues concerning a list of active ingredients identified by established name.\u003C\u002Fp>\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>Your response and any questions regarding the contents of this letter should be sent to compoundinginspections@fda.hhs.gov. In your response, refer to the Warning Letter Number above (#698861) and include a subject line that clearly identifies the submission as a Response to Warning Letter.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>F. Gail Bormel, JD, RPh\u003Cbr>Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJason McGuire\n\nRecipient Title\n\nSenior Vice President, Operations\n\nFagron Compounding Services, LLC dba Fagron Sterile Service\n\n8710 East 34th Street North\n\nWichita, KS 67226-2636\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 698861\n12\u002F19\u002F2024\nDear Mr. McGuire:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on October 2, 2015, and most recently on October 18, 2024. From June 18 to June 28, 2024, an FDA investigator inspected your facility, Fagron Compounding Services, LLC dba Fagron Sterile Services, located at 8710 East 34th Street North, Wichita, KS 67226. During the inspection, the investigator collected evidence that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 to your facility on June 28, 2024. FDA acknowledges receipt of your facility’s responses, dated July 19, 2024, August 30, 2024, September 27, 2024, and October 25, 2024. FDA further acknowledges that on August 15, 2024, your firm initiated a voluntary recall of four lots of Lidocaine HCl Injection, 2% due to lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nIn addition, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\nB. Failure to Meet the Conditions of Section 503B\nDuring the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator collected evidence of the following deficiencies with your facility’s drug product labels:\n1. The drug product label did not include the dosage form. Examples include: Tropicamide 1%\u002FCyclopentolate 1%\u002FPhenylephrine 2.5%\u002FKetorolac 0.5%, 5mL and Fentanyl Citrate 2mcg\u002FmL (100mcg\u002F50mL)\u002FRopivacaine HCl 0.15% (1.5mg\u002FmL) (75mg\u002F50mL).\n2. The drug product label did not include the established name of the drug. Examples include: Tropicamide 1%\u002FCyclopentolate 1%\u002FPhenylephrine 2.5%\u002FKetorolac 0.5%, 5mL; Sodium Citrate 4% (40mg\u002FmL) containing Gentamicin 320mcg\u002FmL Injection, 3mL, 5 mL, and 30 mL; and Epinephrine (1mg\u002FmL), Sterile Solution for Injection.\n3. The drug product label did not include a list of active ingredients identified by established name. Examples include: Tropicamide 1%\u002FCyclopentolate 1%\u002FPhenylephrine 2.5%\u002FKetorolac 0.5%, 5mL; Sodium Citrate 4% (40mg\u002FmL) containing Gentamicin 320mcg\u002FmL Injection, 3mL, 5 mL, and 30 mL; and Epinephrine (1mg\u002FmL), Sterile Solution for Injection.\nFurther, the investigator collected evidence of the following deficiencies with your facility’s container labels:\n1. The container from which the individual units of the drug are removed for dispensing or for administration did not include directions for use, including, as appropriate, dosage and administration. Examples include: Epinephrine (1mg\u002FmL), Sterile Solution for Injection; Phenol Injection 6% (60 mg\u002FmL), in Sterile Water for Injection, 10 mL in Multi-Dose Vial; Sodium Citrate 4% (40mg\u002FmL) containing Gentamicin 320mcg\u002FmL Injection, 3mL, 5 mL, and 30 mL; and Dexamethasone Sodium Phosphate 10 mg\u002FmL Solution for Injection, 2 mL in Multi-Dose Vial.\n2. The container from which the individual units of the drug are removed for dispensing or for administration did not include a list of active ingredients identified by established name. Examples include: Tropicamide 1%\u002FCyclopentolate 1%\u002FPhenylephrine 2.5%\u002FKetorolac 0.5%, 5mL; Sodium Citrate 4% (40mg\u002FmL) containing Gentamicin 320mcg\u002FmL Injection, 3mL, 5 mL, and 30 mL; and Epinephrine (1mg\u002FmL), Sterile Solution for Injection.\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\nSpecific violations are described below.\nC. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that.\n1. You did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\n2. Your firm produced drug products while construction was underway without adequate controls to prevent contamination of the product environment and products.\nThe FDA investigator also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n2. Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition (21 CFR 211.56(a)).\n3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nUnapproved New Drug Products\nYou do not have any FDA-approved applications on file for drug products that you compound.3 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\nMisbranded Drug Products\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.4 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\nD. Corrective Actions\nWe have reviewed your facility’s responses to the Form FDA 483. We acknowledge your firm’s recall of four lots of Lidocaine HCl Injection, 2% due to lack of sterility assurance.\nSome of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions due to lack of adequate supporting documentation. Pertaining to the Chaetomium globosum recovery referenced, you stated the operator “was in training at the time of the recovery.” The investigation into the recovery, DEV-2024-0174, states the operator, “was not fully trained” and “left unsupervised by a qualified trainer, which is a deviation” from procedure. Your firm identified this deviation after reviewing footage of batch (b)(4). However, upon discovering this deviation, your investigation did not expand to other lots produced or operations conducted by the “not fully trained” operator.\nSome of your corrective actions appear deficient. You stated in your response, “For the personnel samples, the samples were taken after the completion of the (b)(4) process, prior to removal of waste and disinfection\u002Fsanitization of the ISO 5 hood and equipment. In review of the batch record, the operators for Succinylcholine lot (b)(4), Rocuronium lot (b)(4) and Lidocaine lot (b)(4) had performed staging, support and (b)(4) activities prior to taking the glove samples. This included sanitizing materials into the hood, removing filled bags, insertion of sterile needle into the bag ports and batch record documentation. None of these activities impacted the filling of the child batches as each child batch did not have a recovery and sterility testing for each passed.” We disagree with your assessment. The operator was involved in critical process parameters, including (b)(4) of the parent batch. This parent batch was used to fill four child batches. The child batches were not (b)(4). We acknowledge your recall of child batches of the parent lot: Lidocaine HCl 2%, Lot# (b)(4), within expiry on August 9, 2024.\nPlease note, microbial contamination, when present, is not uniformly distributed within a batch; therefore, it may not be identified in a sterility test. Compounding facilities producing drug products intended to be sterile under insanitary conditions should not rely upon or cite a passing sterility test result as an indication of product sterility.\nWe acknowledge your commitments in response to our concerns noted with your upcoming facility expansion. During the next FDA inspection, we will assess the potential impact of the upcoming planned construction activities on the quality of sterile drug products that were produced and distributed to patients.\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nIn addition, regarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You have initiated CAPA-2024-0105 and CAPA-2024-0106 to address label issues concerning dosage form, established name of the drug and directions for use. However, no corrective actions have been provided to the agency to address label issues concerning a list of active ingredients identified by established name.\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nE. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nYour response and any questions regarding the contents of this letter should be sent to compoundinginspections@fda.hhs.gov. In your response, refer to the Warning Letter Number above (#698861) and include a subject line that clearly identifies the submission as a Response to Warning Letter.\nSincerely,\n\u002FS\u002F\nF. Gail Bormel, JD, RPh\nDirector\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n3 The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n4 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","Fagron Compounding Services, LLC dba Fagron Sterile Service","fagron-compounding-services-llc-dba-fagron-sterile-service-698861-12192024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffagron-compounding-services-llc-dba-fagron-sterile-service-698861-12192024","2026-10-26T08:08:39.478933+00:00","2025-02-04","698861","Jason McGuire","2026-08-19T17:02:54.213+00:00","VIA Electronic Mail","2024-12-19",{"id":52,"raw":53,"subject":57,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":18,"fei_number":19,"letter_url":62,"updated_at":63,"action_type":22,"case_status":23,"posted_date":64,"marcs_cms_no":65,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":66,"delivery_method":67,"recipient_title":19,"reference_number":19,"action_taken_date":68,"medical_device_id":19,"response_letter_date":19},659,[54,55,56,11,57,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmatthew-stern-ceo-mystart-health-llc-714755-09092025\">Matthew Stern, CEO MyStart Health LLC. \u003C\u002Fa>","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Matthew Stern, CEO MyStart Health LLC. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>254 Chapman Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>STE: 208 #17801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Newark\u003C\u002Fspan>, \u003Cspan>DE\u003C\u002Fspan> \u003Cspan>19702\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@mystarthealth.com\"> support@mystarthealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Mr. Stern:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.mystarthealth.com in August 2025 and has observed that your website offers compounded semaglutide.\u003Ca id=\"footnoteref1_5r4n7li\" href=\"#footnote1_5r4n7li\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning your compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning your compounded semaglutide products appear on your website:\u003C\u002Fp>\u003Cp>• “Generic Ozempic”\u003Cbr>• &nbsp;“Save with generics that offer the same active ingredients and results.”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_2pu4cij\" href=\"#footnote2_2pu4cij\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D. Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_5r4n7li\">\u003Ca href=\"#footnoteref1_5r4n7li\">1\u003C\u002Fa>The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_2pu4cij\">\u003Ca href=\"#footnoteref2_2pu4cij\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMatthew Stern, CEO MyStart Health LLC.\n\n254 Chapman Rd.\n\nSTE: 208 #17801\n\nNewark, DE 19702\n\nUnited States\n\nsupport@mystarthealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nMr. Stern:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.mystarthealth.com in August 2025 and has observed that your website offers compounded semaglutide.1 As described below, your claims concerning your compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning your compounded semaglutide products appear on your website:\n• “Generic Ozempic”\n• “Save with generics that offer the same active ingredients and results.”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002Fs\u002F\nGeorge Tidmarsh, M.D., Ph.D. Director\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Matthew Stern, CEO MyStart Health LLC.","matthew-stern-ceo-mystart-health-llc-714755-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmatthew-stern-ceo-mystart-health-llc-714755-09092025","2026-10-26T08:09:21.704427+00:00","2025-09-16","714755","2026-08-19T16:23:39.346+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2025-09-09",{"id":70,"raw":71,"subject":76,"body_html":77,"body_text":78,"firm_name":79,"letter_id":80,"created_at":81,"fei_number":19,"letter_url":82,"updated_at":83,"action_type":22,"case_status":23,"posted_date":84,"marcs_cms_no":85,"product_type":26,"closeout_date":19,"issuing_office":75,"recipient_name":86,"body_fetched_at":87,"delivery_method":88,"recipient_title":19,"reference_number":19,"action_taken_date":89,"medical_device_id":19,"response_letter_date":19},2412,[72,73,74,75,76,13,13,13],"\u003Ctime datetime=\"2022-10-04T13:20:00Z\">10\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-27T04:00:00Z\">09\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsterling-pharmaceutical-services-llc-629019-09272022\">Sterling Pharmaceutical Services, LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert T. Flynn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sterling Pharmaceutical Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>109 S 2nd St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dupo\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>62239\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 27, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL #629019\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Flynn:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sterling Pharmaceutical Services, LLC, FEI 3009705561, at 109 S 2nd Street, Dupo, Illinois, from February 7 to 18, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, the FDA reviewed the product labels for \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” collected during an inspection of your facility between February 7, 2022 and February 18, 2022. Based on our review, these products are unapproved new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355. Introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d), 355(a). In addition, your firm has significant violations of CGMP regulations. Your firm’s poor manufacturing practices are particularly concerning because many of your products, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” are ophthalmic and directed for use in young children.\u003Cbr>\n\u003Cbr>\nWe reviewed your March 14, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a contract manufacturer of sterile over-the-counter and homeopathic ophthalmic drug products utilizing aseptic processing. You identified your aseptic processing lines as Restricted Access Barrier Systems (RABS). However, your systems permitted access to the processing line (e.g., use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) without the design of rigid wall enclosures. Furthermore, you lacked other fundamental elements of a valid RABS design including glove ports which are employed to reduce or eliminate direct operator interventions into the ISO 5 critical area. These glove ports and infrequent door openings provide the foundation for the overall design and control concept of a RABS that reduces the hazard of ingress of contamination from the surrounding aseptic processing cleanroom environment. Your processing lines lacked basic design features to enable them to be categorized as a RABS.\u003C\u002Fp>\n\n\u003Cp>You did not adequately investigate the excursions above your action limit, including an adverse trend of microbiological contamination from your aseptic processing line environment. For example, from January 1 to December 31, 2021, your environmental monitoring (EM) program repeatedly recovered microorganisms from production line ISO 5 areas (air, surface, and personnel) in your facility.\u003C\u002Fp>\n\n\u003Cp>Your EM results from January 1 to February 16, 2022, including ISO 5 areas and aseptic processing operator glove samples, showed an adverse trend that revealed compromised environmental control of your aseptic processing operation. You continued ophthalmic drug production without adequate investigation and preventive measures to address the persistent microbiological contamination in your ISO 5 environments that posed a risk to product sterility.\u003C\u002Fp>\n\n\u003Cp>Specific incident investigations into these contamination risks routinely identified poor aseptic behavior by personnel and concluded there was a “very low” risk to drug products. Your investigations were inadequate because they did not thoroughly address the persistent adverse trend of microorganisms recovered from ISO 5 areas, including spore-forming bacteria and fungi.\u003C\u002Fp>\n\n\u003Cp>Environmental monitoring of your cleanrooms also recovered gram negative bacterial contamination.\u003C\u002Fp>\n\n\u003Cp>Moreover, on July 7, 2021, your firm detected a sterility failure for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, contaminated with \u003Cem>Herbaspirillum aquaticum\u003C\u002Fem>, a gram-negative bacterium. Non-sterile ophthalmic drugs pose unacceptable risks to patients. We acknowledge that you rejected this lot, however your investigation failed to consider that this sterility failure, in conjunction with your adverse EM trends, may be indicative of contamination risks from the basic design of your processing lines and could impact other batches.\u003C\u002Fp>\n\n\u003Cp>It should be noted that a sterility test, while a critical quality control for aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release drug product batches as the test is only the last in a series of design provisions and controls intended to protect the consumer from distribution of an unsafe batch. Any finished product positive sterility test results represent a serious CGMP issue requiring prompt and comprehensive investigation. Furthermore, your firm’s absence of strict adherence to proper design, aseptic methods, and environmental controls undermine your daily assurance of consistent sterile manufacturing.\u003C\u002Fp>\n\n\u003Cp>In your response you indicate that you conducted a retrospective evaluation of all microbiological monitoring results between January 2021, and March 2022, and concluded that there was no impact to the lots previously released. Your response is inadequate as your retrospective review relied on third-party sterility testing, smoke studies, personnel training, and processes, but failed to consider that persistently deficient environmental controls are likely rooted in fundamental facility or equipment design flaws. In addition to line design hazards that fundamentally compromise aseptic processing, you performed makeshift line modification within the ISO 5 areas using materials that can harbor bioburden (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>A vigilant ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities including, but not be limited to:\u003Cbr>\n&nbsp; o All human interactions with the ISO 5 area\u003Cbr>\n&nbsp; o Equipment placement and suitability, including ergonomics for each human interaction\u003Cbr>\n&nbsp; o Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\u003Cbr>\n&nbsp; o Facility layout\u003Cbr>\n&nbsp; o Personnel flows and material flows throughout all rooms used to support and conduct sterile operations\u003Cbr>\n&nbsp; o Building management systems\u003C\u002Fp>\n\n\u003Cp>• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA will robustly remediate your deficient sterile manufacturing operation. Include comprehensive changes\u002Fimprovements in the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive and independent assessment of your ongoing use of a rapid sterility testing method for ophthalmic drug products produced on an aseptic line that requires frequent human intervention. Include the independent assessment to evaluate whether the method is equivalent to or better than USP &lt;71&gt; sterility test.\u003C\u002Fp>\n\n\u003Cp>• A summary of your program for qualifying and overseeing the contract laboratory performing testing of drug products you manufacture. Include a detailed assessment to determine if the laboratory is qualified to do the tests and all batch testing performed on your behalf is satisfactory.\u003C\u002Fp>\n\n\u003Cp>• A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, sterility testing via compendial method of each batch. If testing yields an out of specification result or unexplained discrepancy, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>• An independent assessment of your EM program including, but not limited to, investigating deviations from microbiological limits. Include your plan for implementing the recommendations in the assessment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your EM program (including personnel monitoring) was inadequate for classified areas used for the production of sterile ophthalmic drug products. We observed instances during production of two lots of sterile eye drops in which your firm failed to ensure adequate monitoring of non-viable particulates (NVP).\u003C\u002Fp>\n\n\u003Cp>Furthermore, personnel monitoring was insufficient. Monitoring was limited to operators’ gloved hands following aseptic interventions. Because of the significant gaps within your EM program, you have insufficient information to assess the quality of the aseptic processing environment.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you did not provide the recovered NVP data and describe how you recovered the data (which you stated during the inspection was unrecoverable). You also did not determine how many batches may have been affected by your identified root cause.\u003C\u002Fp>\n\n\u003Cp>Further, your response indicated that you made procedural changes to incorporate occasional monitoring of arms and hoods of personnel gowns based on your risk assessment (V22-00602.RA). However, your response is inadequate because it fails to consider potential basic design issues with your aseptic processing line as supported by the nature and frequency of personnel aseptic interventions, manually intensive activities, EM data, aseptic breaches, and line maintenance manipulations. For example, in your response, you failed to include justification for omitting samples of personnel goggles and chest as well as aseptic processing line \u003Cstrong>(b)(4)\u003C\u002Fstrong> from EM. Environmental monitoring should promptly identify potential routes of contamination, allowing for implementation of corrections before product contamination could occur.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent review of your personnel and EM program, including but not limited to:\u003Cbr>\n&nbsp; o A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbiological trends from your classified areas. Provide an updated timeline for implementation of your improved program, including procedural changes.\u003Cbr>\n&nbsp; o A risk assessment based on a retrospective review of personnel and EM data since you initiated sterile manufacturing of ophthalmic drug products. This assessment should include a review of all batches likely affected by gaps in NVP data.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm had not established adequate procedures designed to prevent microbiological contamination risks in your facility. For example, your firm did not routinely document interventions performed by aseptic processing area operators during production. In addition, our investigators observed poor aseptic behaviors.\u003C\u002Fp>\n\n\u003Cp>Investigators observed operators repeatedly exhibiting poor aseptic behaviors during filling operations of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. To perform interventions during aseptic operations, the design of your filling line required personnel to reach through a \u003Cstrong>(b)(4)\u003C\u002Fstrong> placed in front of the aseptic processing equipment where open processing of finished product occurred. Operators were also observed contacting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with their goggles and chest area of their gowns while leaning into the ISO 5 zone to perform aseptic interventions. Additionally, operators did not sanitize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>, although it was required by your procedures for interventions. Among other factors, adequate separation, proper line design and control, robust sterilization and disinfection, a vigilant EM program, and strict personnel adherence to aseptic practices are essential to prevent contamination.\u003C\u002Fp>\n\n\u003Cp>Our investigators also observed that non-routine interventions performed by aseptic operators were not recorded. The exclusion of this data inhibits adequate quality evaluations and investigations into deficiencies and compromises your ability to ensure media fills accurately simulate the number and type of interventions that occur during commercial manufacturing.\u003C\u002Fp>\n\n\u003Cp>Your response includes changes to batch record documentation and procedures for qualification of aseptic operators along with applicable training. However, your response fails to acknowledge potential design issues (e.g., equipment ergonomic flaws that influence operator behaviors), excessive need for manual manipulations, and insufficiency of barrier protection to provide adequate separation from surrounding areas.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\u003C\u002Fp>\n\n\u003Cp>• A thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Statements on the product labels that provide evidence of the intended uses of these products include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> . . . ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Supports: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Ointment\u003C\u002Fstrong>\u003Cbr>\n• The product name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is located together on the label with “Drug Facts . . . Directions . . . \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> . . . ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Ointment\u003C\u002Fstrong>\u003Cbr>\n• The product name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is located together on the label with “Drug Facts . . . Directions . . . \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Ointment\u003C\u002Fstrong>\u003Cbr>\n• The product name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is located together on the label with “Drug Facts . . . Directions . . . \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\n\n\u003Cp>The above claims for \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” demonstrate that they are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Moreover, these products are “new drugs,” as defined by 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>We recognize that \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” are labeled as homeopathic drugs with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Brian D. Garthwaite, Ph. D.\u003Cbr>\nCompliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Case Number above (#629019). If you have questions regarding the contents of this letter, please contact Dr. Garthwaite at (612) 758-7132.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Jeffrey Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert T. Flynn\n\nRecipient Title\n\nChief Executive Officer\n\nSterling Pharmaceutical Services, LLC\n\n109 S 2nd St.\n\nDupo, IL 62239\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nSeptember 27, 2022\n\nWARNING LETTER\n\nWL #629019\n\nDear Mr. Flynn:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sterling Pharmaceutical Services, LLC, FEI 3009705561, at 109 S 2nd Street, Dupo, Illinois, from February 7 to 18, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, the FDA reviewed the product labels for (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4),” collected during an inspection of your facility between February 7, 2022 and February 18, 2022. Based on our review, these products are unapproved new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355. Introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d), 355(a). In addition, your firm has significant violations of CGMP regulations. Your firm’s poor manufacturing practices are particularly concerning because many of your products, such as (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4),” are ophthalmic and directed for use in young children.\n\nWe reviewed your March 14, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour firm is a contract manufacturer of sterile over-the-counter and homeopathic ophthalmic drug products utilizing aseptic processing. You identified your aseptic processing lines as Restricted Access Barrier Systems (RABS). However, your systems permitted access to the processing line (e.g., use of (b)(4)) without the design of rigid wall enclosures. Furthermore, you lacked other fundamental elements of a valid RABS design including glove ports which are employed to reduce or eliminate direct operator interventions into the ISO 5 critical area. These glove ports and infrequent door openings provide the foundation for the overall design and control concept of a RABS that reduces the hazard of ingress of contamination from the surrounding aseptic processing cleanroom environment. Your processing lines lacked basic design features to enable them to be categorized as a RABS.\n\nYou did not adequately investigate the excursions above your action limit, including an adverse trend of microbiological contamination from your aseptic processing line environment. For example, from January 1 to December 31, 2021, your environmental monitoring (EM) program repeatedly recovered microorganisms from production line ISO 5 areas (air, surface, and personnel) in your facility.\n\nYour EM results from January 1 to February 16, 2022, including ISO 5 areas and aseptic processing operator glove samples, showed an adverse trend that revealed compromised environmental control of your aseptic processing operation. You continued ophthalmic drug production without adequate investigation and preventive measures to address the persistent microbiological contamination in your ISO 5 environments that posed a risk to product sterility.\n\nSpecific incident investigations into these contamination risks routinely identified poor aseptic behavior by personnel and concluded there was a “very low” risk to drug products. Your investigations were inadequate because they did not thoroughly address the persistent adverse trend of microorganisms recovered from ISO 5 areas, including spore-forming bacteria and fungi.\n\nEnvironmental monitoring of your cleanrooms also recovered gram negative bacterial contamination.\n\nMoreover, on July 7, 2021, your firm detected a sterility failure for (b)(4), lot (b)(4), contaminated with Herbaspirillum aquaticum, a gram-negative bacterium. Non-sterile ophthalmic drugs pose unacceptable risks to patients. We acknowledge that you rejected this lot, however your investigation failed to consider that this sterility failure, in conjunction with your adverse EM trends, may be indicative of contamination risks from the basic design of your processing lines and could impact other batches.\n\nIt should be noted that a sterility test, while a critical quality control for aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release drug product batches as the test is only the last in a series of design provisions and controls intended to protect the consumer from distribution of an unsafe batch. Any finished product positive sterility test results represent a serious CGMP issue requiring prompt and comprehensive investigation. Furthermore, your firm’s absence of strict adherence to proper design, aseptic methods, and environmental controls undermine your daily assurance of consistent sterile manufacturing.\n\nIn your response you indicate that you conducted a retrospective evaluation of all microbiological monitoring results between January 2021, and March 2022, and concluded that there was no impact to the lots previously released. Your response is inadequate as your retrospective review relied on third-party sterility testing, smoke studies, personnel training, and processes, but failed to consider that persistently deficient environmental controls are likely rooted in fundamental facility or equipment design flaws. In addition to line design hazards that fundamentally compromise aseptic processing, you performed makeshift line modification within the ISO 5 areas using materials that can harbor bioburden (e.g., (b)(4)).\n\nA vigilant ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities including, but not be limited to:\n\no All human interactions with the ISO 5 area\n\no Equipment placement and suitability, including ergonomics for each human interaction\n\no Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\n\no Facility layout\n\no Personnel flows and material flows throughout all rooms used to support and conduct sterile operations\n\no Building management systems\n\n• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA will robustly remediate your deficient sterile manufacturing operation. Include comprehensive changes\u002Fimprovements in the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\n\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\n\n• A comprehensive and independent assessment of your ongoing use of a rapid sterility testing method for ophthalmic drug products produced on an aseptic line that requires frequent human intervention. Include the independent assessment to evaluate whether the method is equivalent to or better than USP \u003C71> sterility test.\n\n• A summary of your program for qualifying and overseeing the contract laboratory performing testing of drug products you manufacture. Include a detailed assessment to determine if the laboratory is qualified to do the tests and all batch testing performed on your behalf is satisfactory.\n\n• A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, sterility testing via compendial method of each batch. If testing yields an out of specification result or unexplained discrepancy, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\n• An independent assessment of your EM program including, but not limited to, investigating deviations from microbiological limits. Include your plan for implementing the recommendations in the assessment.\n\n2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\nYour EM program (including personnel monitoring) was inadequate for classified areas used for the production of sterile ophthalmic drug products. We observed instances during production of two lots of sterile eye drops in which your firm failed to ensure adequate monitoring of non-viable particulates (NVP).\n\nFurthermore, personnel monitoring was insufficient. Monitoring was limited to operators’ gloved hands following aseptic interventions. Because of the significant gaps within your EM program, you have insufficient information to assess the quality of the aseptic processing environment.\n\nYour response is inadequate because you did not provide the recovered NVP data and describe how you recovered the data (which you stated during the inspection was unrecoverable). You also did not determine how many batches may have been affected by your identified root cause.\n\nFurther, your response indicated that you made procedural changes to incorporate occasional monitoring of arms and hoods of personnel gowns based on your risk assessment (V22-00602.RA). However, your response is inadequate because it fails to consider potential basic design issues with your aseptic processing line as supported by the nature and frequency of personnel aseptic interventions, manually intensive activities, EM data, aseptic breaches, and line maintenance manipulations. For example, in your response, you failed to include justification for omitting samples of personnel goggles and chest as well as aseptic processing line (b)(4) from EM. Environmental monitoring should promptly identify potential routes of contamination, allowing for implementation of corrections before product contamination could occur.\n\nIn response to this letter, provide:\n\n• A comprehensive independent review of your personnel and EM program, including but not limited to:\n\no A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbiological trends from your classified areas. Provide an updated timeline for implementation of your improved program, including procedural changes.\n\no A risk assessment based on a retrospective review of personnel and EM data since you initiated sterile manufacturing of ophthalmic drug products. This assessment should include a review of all batches likely affected by gaps in NVP data.\n\n3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nYour firm had not established adequate procedures designed to prevent microbiological contamination risks in your facility. For example, your firm did not routinely document interventions performed by aseptic processing area operators during production. In addition, our investigators observed poor aseptic behaviors.\n\nInvestigators observed operators repeatedly exhibiting poor aseptic behaviors during filling operations of (b)(4), Lot (b)(4). To perform interventions during aseptic operations, the design of your filling line required personnel to reach through a (b)(4) placed in front of the aseptic processing equipment where open processing of finished product occurred. Operators were also observed contacting the (b)(4) with their goggles and chest area of their gowns while leaning into the ISO 5 zone to perform aseptic interventions. Additionally, operators did not sanitize the (b)(4) with sterile (b)(4), although it was required by your procedures for interventions. Among other factors, adequate separation, proper line design and control, robust sterilization and disinfection, a vigilant EM program, and strict personnel adherence to aseptic practices are essential to prevent contamination.\n\nOur investigators also observed that non-routine interventions performed by aseptic operators were not recorded. The exclusion of this data inhibits adequate quality evaluations and investigations into deficiencies and compromises your ability to ensure media fills accurately simulate the number and type of interventions that occur during commercial manufacturing.\n\nYour response includes changes to batch record documentation and procedures for qualification of aseptic operators along with applicable training. However, your response fails to acknowledge potential design issues (e.g., equipment ergonomic flaws that influence operator behaviors), excessive need for manual manipulations, and insufficiency of barrier protection to provide adequate separation from surrounding areas.\n\nIn response to this letter, provide:\n\n• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\n\n• A thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\n\nUnapproved New Drugs\n\nStatements on the product labels that provide evidence of the intended uses of these products include, but are not limited to, the following:\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) . . . ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Supports: ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Ointment\n\n• The product name “(b)(4),” which is located together on the label with “Drug Facts . . . Directions . . . (b)(4).”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) . . . ● (b)(4)”\n\n“(b)(4)” Sterile Eye Ointment\n\n• The product name “(b)(4),” which is located together on the label with “Drug Facts . . . Directions . . . (b)(4).”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Ointment\n\n• The product name “(b)(4),” which is located together on the label with “Drug Facts . . . Directions . . . (b)(4).”\n\nThe above claims for (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4)” demonstrate that they are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Moreover, these products are “new drugs,” as defined by 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nWe recognize that (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4)” are labeled as homeopathic drugs with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or approval.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nCGMP Consultant Recommended\n\nWe acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nAdditional Guidance on Aseptic Processing\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Brian D. Garthwaite, Ph. D.\n\nCompliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter Case Number above (#629019). If you have questions regarding the contents of this letter, please contact Dr. Garthwaite at (612) 758-7132.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Jeffrey Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\ncc: (b)(4)","Sterling Pharmaceutical Services, LLC","sterling-pharmaceutical-services-llc-629019-09272022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsterling-pharmaceutical-services-llc-629019-09272022","2026-10-26T08:10:05.992438+00:00","2022-10-04","629019","Robert T. Flynn","2026-08-20T01:31:42.647+00:00","UPS Next Day","2022-09-27",{"id":91,"raw":92,"subject":37,"body_html":98,"body_text":99,"firm_name":100,"letter_id":101,"created_at":81,"fei_number":19,"letter_url":102,"updated_at":103,"action_type":22,"case_status":23,"posted_date":104,"marcs_cms_no":105,"product_type":26,"closeout_date":19,"issuing_office":96,"recipient_name":106,"body_fetched_at":107,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":108,"medical_device_id":19,"response_letter_date":19},2373,[93,94,95,96,97,13,13,13],"\u003Ctime datetime=\"2022-11-01T13:20:00Z\">11\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-21T04:00:00Z\">10\u002F21\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnephron-pharmaceuticals-corporation-dba-nephron-sterile-compounding-center-llc-644180-10212022\">Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC\u003C\u002Fa>","Office of Pharmaceutical Quality Operations, Division II","Compounding Pharmacy\u002FAdulterated Drug Products ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Lou Wood Kennedy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO and Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4500 12th Street Extension\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Columbia\u003C\u002Fspan>, \u003Cspan>SC\u003C\u002Fspan> \u003Cspan>29172-3025\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 10\u002F21\u002F2022\u003Cbr>\nCase #: 644180\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Kennedy:\u003C\u002Fp>\n\n\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on July 15, 2014 and reregistered most recently on January 20, 2022. From March 28, 2022 to April 20, 2022, FDA investigators inspected your facility, Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC located at 4500 12th Street Extension, West Columbia, SC 29172. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your facility on April 20, 2022. FDA acknowledges receipt of your facility’s responses, dated May 10, 2022, June 2, 2022, June 22, 2022, and July 22, 2022. We acknowledge that on May 18, 2022, and June 30, 2022, your firm initiated voluntary recalls of certain drug products intended to be sterile that were within expiry due to a lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>In addition, for a drug product compounded using bulk drug substances to qualify for exemptions under section 503B, the bulk drug substances that are used must appear on a list established by the Secretary identifying bulk drug substances for which there is a clinical need (“503B bulks list”), or the compounded drug must appear on the drug shortage list in effect under section 506E of the FDCA at the time of compounding, distribution, and dispensing (section 503B(a)(2)(A) of the FDCA [21 U.S.C. § 353b(a)(2)(A)]).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, FDA investigators noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators noted that your facility compounded drug products using glycopyrrolate. Drug products compounded using this bulk drug substance are not eligible for the exemptions provided by section 503B, because it does not appear on the 503B bulks list, and is not used to compound a drug that appears on the drug shortage list.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. You did not take appropriate corrective actions, nor did you perform adequate product evaluation after approximately 1686 excursions of microbial contamination were recovered within the ISO 5 aseptic processing area.\u003C\u002Fp>\n\n\u003Cp>2. Your media fills were not performed under the most challenging or stressful conditions such as failing to simulate the largest batch size produced at your firm. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>FDA investigators also noted CGMP violations at your facility, that caused your drug product(s) to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21CFR113(b)).\u003C\u002Fp>\n\n\u003Cp>5. Your firm failed to maintain written production, control, or distribution records specifically associated with a batch of a drug product for at least one year after the expiration date of the batch (CFR 211.180(a)).\u003C\u002Fp>\n\n\u003Cp>6. Laboratory records are deficient in that they do not include the initials and signature of the second person reviewing the record for accuracy (21 CFR 211.194 (a)(8)).\u003C\u002Fp>\n\n\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human&nbsp;\u003C\u002Fem>\u003Cem>Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. We acknowledge your recall of drug products intended to be sterile due to a lack of sterility assurance on May 18, 2022, and June 30, 2022. Furthermore, we acknowledge that you acquired a third party consultant to assist you with your evaluation.\u003C\u002Fp>\n\n\u003Cp>We are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\n\n\u003Cp>In response to observation 3 of the Form FDA 483, you committed to discontinue the use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and instead implement USP &lt;71&gt; for the sterility testing of all your 503B drug products. However, your response did not include:\u003C\u002Fp>\n\n\u003Cp>1. A USP &lt;71&gt; sterility test validation timeline for each product;\u003Cbr>\n2. A \u003Cstrong>(b)(4)\u003C\u002Fstrong> discontinuation date;\u003Cbr>\n3. An investigation into all the products that were associated with excess events; and\u003Cbr>\n4. A determination of the impact on the sterility assurance of each of the effected products involved in the excess event excursions.\u003C\u002Fp>\n\n\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>In response to observation 2 of the Form FDA 483, you stated that you have modified your environmental monitoring, EM, and personnel monitoring, PM, limits such that any microbial contamination in the ISO 5 aseptic processing area will be investigated. However, you did not provide a determination of the impact on the sterility assurance of each of the affected products that were manufactured when EM\u002FPM exceeded \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs. Additionally, there was a lack of transparency regarding the identification of all products\u002Flots affected by the substandard EM\u002FPM within your recall and post market assessment.\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\n\n\u003Cp>Furthermore, regarding observations related to the conditions of section 503B of the FDCA, your corrective actions appear adequate: you state that you have “ceased manufacturing and distribution of Glycopyrrolate Injection, USP” and that the “drug product was removed from the online ordering system as of April 4, 2022, and is not available for purchase.”\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>644180\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Dayna I. Martinez, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to dayna.matinez@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Dayna I. Martinez via phone at 787-729-8608 or email at dayna.martinez@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Frances de Jesus\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The glycopyrrolate bulk drug substance is not on the 503B bulks list and cannot be used for compounding consistent with section 503B(a)(2) unless it is used to compound a drug that appears on FDA’s drug shortage list. Glycopyrrolate was nominated for inclusion on the 503B bulks list; FDA evaluated glycopyrrolate and, on January 27, 2022, determined that there is not a clinical need for outsourcing facilities to compound drug products using this bulk drug substance under section 503B of the FD&amp;C Act. For additional information, see 87 \u003Cem>Fed. Reg\u003C\u002Fem>. 4240, available at https:\u002F\u002Fwww.govinfo.gov\u002Fcontent\u002Fpkg\u002FFR-2022-01-27\u002Fpdf\u002F2022-01558.pdf. Once FDA has published in the Federal Register its decision not to place a particular substance on the 503B bulks list, the policy described in section III of the \u003Cem>Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (Revision 1)\u003C\u002Fem> no longer applies.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLou Wood Kennedy\n\nRecipient Title\n\nCEO and Owner\n\nNephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC\n\n4500 12th Street Extension\n\nWest Columbia, SC 29172-3025\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nDATE: 10\u002F21\u002F2022\n\nCase #: 644180\n\nWARNING LETTER\n\nDear Ms. Kennedy:\n\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on July 15, 2014 and reregistered most recently on January 20, 2022. From March 28, 2022 to April 20, 2022, FDA investigators inspected your facility, Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC located at 4500 12th Street Extension, West Columbia, SC 29172. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your facility on April 20, 2022. FDA acknowledges receipt of your facility’s responses, dated May 10, 2022, June 2, 2022, June 22, 2022, and July 22, 2022. We acknowledge that on May 18, 2022, and June 30, 2022, your firm initiated voluntary recalls of certain drug products intended to be sterile that were within expiry due to a lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA.\n\nA. Compounded Drug Products under the FDCA\n\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\n\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\n\nIn addition, for a drug product compounded using bulk drug substances to qualify for exemptions under section 503B, the bulk drug substances that are used must appear on a list established by the Secretary identifying bulk drug substances for which there is a clinical need (“503B bulks list”), or the compounded drug must appear on the drug shortage list in effect under section 506E of the FDCA at the time of compounding, distribution, and dispensing (section 503B(a)(2)(A) of the FDCA [21 U.S.C. § 353b(a)(2)(A)]).\n\nB. Failure to Meet the Conditions of Section 503B\n\nDuring the inspection, FDA investigators noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators noted that your facility compounded drug products using glycopyrrolate. Drug products compounded using this bulk drug substance are not eligible for the exemptions provided by section 503B, because it does not appear on the 503B bulks list, and is not used to compound a drug that appears on the drug shortage list.3\n\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nFDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. You did not take appropriate corrective actions, nor did you perform adequate product evaluation after approximately 1686 excursions of microbial contamination were recovered within the ISO 5 aseptic processing area.\n\n2. Your media fills were not performed under the most challenging or stressful conditions such as failing to simulate the largest batch size produced at your firm. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\nFDA investigators also noted CGMP violations at your facility, that caused your drug product(s) to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n\n1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\n2. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\n4. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21CFR113(b)).\n\n5. Your firm failed to maintain written production, control, or distribution records specifically associated with a batch of a drug product for at least one year after the expiration date of the batch (CFR 211.180(a)).\n\n6. Laboratory records are deficient in that they do not include the initials and signature of the second person reviewing the record for accuracy (21 CFR 211.194 (a)(8)).\n\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for drug products that you compound.4 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\n\nMisbranded Drug Products\n\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.5 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your facility’s responses to the Form FDA 483. We acknowledge your recall of drug products intended to be sterile due to a lack of sterility assurance on May 18, 2022, and June 30, 2022. Furthermore, we acknowledge that you acquired a third party consultant to assist you with your evaluation.\n\nWe are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n\nIn response to observation 3 of the Form FDA 483, you committed to discontinue the use of the (b)(4) and instead implement USP \u003C71> for the sterility testing of all your 503B drug products. However, your response did not include:\n\n1. A USP \u003C71> sterility test validation timeline for each product;\n\n2. A (b)(4) discontinuation date;\n\n3. An investigation into all the products that were associated with excess events; and\n\n4. A determination of the impact on the sterility assurance of each of the effected products involved in the excess event excursions.\n\nSome of your corrective actions appear deficient:\n\nIn response to observation 2 of the Form FDA 483, you stated that you have modified your environmental monitoring, EM, and personnel monitoring, PM, limits such that any microbial contamination in the ISO 5 aseptic processing area will be investigated. However, you did not provide a determination of the impact on the sterility assurance of each of the affected products that were manufactured when EM\u002FPM exceeded (b)(4) CFUs. Additionally, there was a lack of transparency regarding the identification of all products\u002Flots affected by the substandard EM\u002FPM within your recall and post market assessment.\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\n\nFurthermore, regarding observations related to the conditions of section 503B of the FDCA, your corrective actions appear adequate: you state that you have “ceased manufacturing and distribution of Glycopyrrolate Injection, USP” and that the “drug product was removed from the online ordering system as of April 4, 2022, and is not available for purchase.”\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations.\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\n\nYour written notification should refer to case # 644180.\n\nPlease electronically submit your reply, on company letterhead, to Dayna I. Martinez, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to dayna.matinez@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Dayna I. Martinez via phone at 787-729-8608 or email at dayna.martinez@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nFrances de Jesus\n\nActing Program Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n________________________\n\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n\n3 The glycopyrrolate bulk drug substance is not on the 503B bulks list and cannot be used for compounding consistent with section 503B(a)(2) unless it is used to compound a drug that appears on FDA’s drug shortage list. Glycopyrrolate was nominated for inclusion on the 503B bulks list; FDA evaluated glycopyrrolate and, on January 27, 2022, determined that there is not a clinical need for outsourcing facilities to compound drug products using this bulk drug substance under section 503B of the FD&C Act. For additional information, see 87 Fed. Reg. 4240, available at https:\u002F\u002Fwww.govinfo.gov\u002Fcontent\u002Fpkg\u002FFR-2022-01-27\u002Fpdf\u002F2022-01558.pdf. Once FDA has published in the Federal Register its decision not to place a particular substance on the 503B bulks list, the policy described in section III of the Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (Revision 1) no longer applies.\n\n4 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n5 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC","nephron-pharmaceuticals-corporation-dba-nephron-sterile-compounding-center-llc-644180-10212022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnephron-pharmaceuticals-corporation-dba-nephron-sterile-compounding-center-llc-644180-10212022","2026-10-26T08:09:31.767571+00:00","2022-11-01","644180","Lou Wood Kennedy","2026-08-20T01:28:46.555+00:00","2022-10-21",5,{"510k":111,"classification":112,"enforcement":113,"event":114,"event_backfill":115,"pma":116,"warning_letter":117},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]